Novel Test Predicts Breast Cancer Recurrence and Radiation Therapy Benefit

LAGUNA HILLS, Calif. – March 12, 2026 – A new multi-omic test, AidaBreast™, developed by Prelude Corporation (PreludeDx®), shows promise in predicting the risk of locoregional recurrence and identifying which early-stage breast cancer patients will benefit most from radiation therapy. Results from a large, multi-institutional validation study were recently published in Breast Cancer Research.

Personalizing Radiation Therapy Decisions

For decades, decisions regarding radiation therapy for early-stage invasive breast cancer have relied heavily on clinicopathologic features. Although, these features don’t always fully capture the unique biological behavior of an individual’s tumor. AidaBreast™ aims to address this gap by providing a more personalized assessment of risk and treatment benefit.

“Aida™ is the first and only test designed to provide both prognostic assessment of locoregional recurrence risk and predictive insight into radiation therapy benefit,” said Dr. Naamit Gerber, Radiation Oncologist at NYU Langone Health’s Perlmutter Cancer Center and co-author of the study. ¹ This type of biologic information has not previously been available to guide radiation decision-making and represents an important advancement toward truly personalized care.

Study Details

The validation study evaluated 922 hormone receptor-positive (HR+), HER2-negative invasive women who underwent breast-conserving surgery, with or without adjuvant radiation therapy. The study included data from four academic and clinical centers in the United States and Sweden, with a median follow-up of 10 years. ¹

How AidaBreast™ Works

AidaBreast™ integrates targeted NextGen RNA expression with multiplex protein biomarker expression and spatial biology to provide a comprehensive understanding of tumor biology. ¹ This allows for a more accurate assessment of both recurrence risk and the potential benefit of radiation therapy.

Key Findings

• AidaBreast™ may better inform individualized shared decision-making for radiation therapy treatment.
• The test identified a low-risk group of patients who did not experience a statistically significant benefit from radiation therapy.
• AidaBreast™ identified a subset of patients who experienced a targeted and significant benefit from radiation therapy.
• The test provided information not available from traditional clinicopathology.

Building on DCISionRT®

AidaBreast™ builds upon PreludeDx’s existing technology, DCISionRT®, which is used to guide radiation therapy decisions for women diagnosed with ductal carcinoma in situ (DCIS). ² Together, these tests represent PreludeDx’s commitment to providing biologically driven decision support tools across the spectrum of early-stage breast cancer care.

Future Directions

As breast cancer care continues to evolve towards personalization, multi-omic approaches like AidaBreast™ may play an increasingly important role in aligning treatment intensity with individual patient risk. Further validation studies are ongoing to confirm these findings and expand the clinical utility of AidaBreast™.

“The publication of this study represents an important milestone not only for Aida™, but for PreludeDx as a whole,” said Dan Forche, President and CEO of PreludeDx. ¹

Disclaimer: This article is based on press releases and study data available as of March 12, 2026.

PreludeDx Website